Aarti Pharmalabs at the FY26 Close: Stable Revenue, Softer Profit, and a Capex-Led Growth Setup

Aarti Pharmalabs Limited closed FY26 with revenue that held steady, but profitability that fell sharply on a year-on-year basis. On a standalone basis, operational revenue rose to INR 1,798 crore in FY26 from INR 1,771 crore in FY25, a modest 1.5 percent increase. EBITDA came in at INR 406 crore versus INR 427 crore last year, and EBITDA margin eased to 22.6 percent from 24.0 percent. The bigger hit was to the bottom line. Standalone PAT dropped to INR 176 crore from INR 257 crore in FY25.

The company framed the year around scale and readiness. It highlighted a multi-decade operating base and a wide footprint: 220+ products, 500+ global clients, exports to 50+ countries, 7 manufacturing units, and 3 USFDA units. It also pointed to process development and rapid scale-up capabilities as a core differentiator in both generic APIs and CDMO CMO work. The operational story in FY26 is about holding the top line while absorbing higher depreciation, higher finance costs, and foreign exchange movement, and then setting up the next phase through major capacity additions.

A steady top line, but costs and accounting effects mattered

From a pure operating lens, FY26 did not look like a contraction year in standalone revenue. It was closer to a pause after the stronger expansion from FY24 to FY25. EBITDA still stayed above INR 400 crore, but the margin compressed by about 149 basis points year-on-year.

The detailed standalone profit and loss statement explains why profit looked weaker. Depreciation and amortisation rose to INR 104.3 crore in FY26 from INR 79.1 crore in FY25, a 31.9 percent increase, consistent with recent commissioning and capacity creation. Finance costs increased to INR 46.9 crore from INR 25.6 crore, up 83.2 percent. The company also reported a foreign exchange loss of INR 33.2 crore compared to a gain of INR 1.7 crore in FY25. Together, these items created a bigger drag below EBITDA.

One more factor affected comparability. The company noted that recognition of fair value movement on a long-dated USD forward contract under FVTPL affected reported profitability, and that previous year figures were restated accordingly. In other words, reported earnings trends include accounting volatility linked to hedging instruments, and not only underlying operating performance.

Financial snapshot

Consolidated numbers show a different comparison set

On a consolidated basis, FY26 operational revenue was INR 1,819 crore versus INR 2,115 crore in FY25, a decline of 14.0 percent. EBITDA came in at INR 402 crore versus INR 464 crore, down 13.4 percent, while the EBITDA margin edged up to 22.12 percent from 21.96 percent. Consolidated PAT declined to INR 175 crore from INR 272 crore.

The company cautioned investors that consolidated numbers are not comparable with prior periods because of a change in accounting treatment related to a joint venture. It stated that, as intimated to stock exchanges, the entity related to SHAH with Ganesh Polchem Limited became a joint venture of the company effective April 1, 2025, and consolidated accounts are prepared using the equity method as required by Ind AS.

That caveat is important because it affects how investors read the consolidated trend line. In practice, the standalone numbers can be the cleaner reference for operational trajectory and for linking performance to new site commissioning, capacity utilisation, and cost structure.

Scale, regulatory positioning, and why Xanthine still anchors the story

Aarti Pharmalabs positions itself as a global manufacturer of generic APIs and Xanthine derivatives, and as a leading player in CDMO CMO services. The presentation highlights a regulatory-focused manufacturing setup with accreditations across USFDA, EU GMP, EDQM, KFDA, and COFEPRIS.

Within this portfolio, Xanthine derivatives are a key pillar. The company states a 15 to 20 percent global market share in Xanthine. That is a meaningful claim because it implies both scale and stickiness in long-standing customer relationships. The Tarapur brownfield project described later also indicates management sees a clear path to monetising this position by increasing capacity and wallet share.

At the same time, CDMO CMO appears to be the long runway segment in management’s narrative. The highlight line calls Aarti Pharmalabs one of the leading small molecule CDMO CMO companies in India, with expertise in novel chemistries and a demonstrated ability to develop robust, cost-effective processes for rapid scale up.

Geographically, FY26 sales were 54 percent international and 46 percent domestic. That split suggests two things. First, the company is not dependent on a single market. Second, currency and hedging policies can materially affect reported earnings, especially in years where foreign exchange moves against expectations, as seen in the FY26 foreign exchange loss line.

Capex as the bridge from a softer FY26 to a stronger medium-term plan

The most forward-looking part of the presentation is the investment pipeline. Management is effectively asking investors to look through near-term margin noise and focus on capacity and capability being built now.

Atali greenfield project

Atali in Gujarat is the flagship growth engine for intermediates and CDMO CMO. Phase 1 block capacity is about 450 KL, with estimated investment of INR 400 crore. The site has 80 acres available, and the company states the future potential is scalable up to 8 to 10 times Phase 1 capacity. Around 80 percent capacity was operationalized by Q4FY26.

Strategically, Atali serves two stated objectives. First, it provides a growth engine for CDMO CMO with expansion potential. Second, it enhances backward integration through expanded intermediates capacity. Those are not abstract points. In API and CDMO businesses, intermediates and process control can directly affect cost competitiveness, lead times, and reliability of supply. The Atali build-out therefore is likely to influence both margin resilience and the ability to win more complex or longer-duration projects.

Tarapur brownfield expansion

The Tarapur expansion focuses on Xanthine derivatives. The project has an estimated investment of INR 210 crore and aims to raise proposed capacity to 9,000 MTPA from current utilisation of 6,000 MTPA. The company expects it to be operationalized in Q1FY27.

The strategic rationale is clearly framed around customer relationships and mix improvement. Beverage sales are said to be predominantly driven by long-standing client relationships, supporting consistency of revenue. With additional capacity, the company aspires to gain a larger wallet share with beverage customers. It also aims to increase share in pharmaceutical grade Xanthine derivatives to expand margins.

These points matter because they outline a two-step approach to monetisation. Step one is volume and share gains in an established base. Step two is a shift toward higher value pharmaceutical grade output to support margins.

Medium-term targets and the next capability build

Management set an ambition of 15 to 18 percent revenue and EBITDA CAGR over the next 3 to 4 years. The plan is being backed by capex and R and D investment.

The presentation states that FY26 capex reached about INR 400 crore and the FY27 outlook is expected at similar levels. It also says the company is initiating R and D investment in FY27 towards TIDES, specifically peptides and oligonucleotides, to expand portfolio capabilities. In parallel, it announced capex for Atali Block 2 for specific CDMO CMO projects, with groundbreaking planned in Q3FY27.

The TIDES comment is short, but it signals intent to expand beyond the current base. For investors, the key is not to assume immediate revenue impact from a new R and D theme. Instead, it should be read as a capability option that may widen the addressable opportunity set, especially if CDMO CMO customers demand adjacent platforms.

What investors should take away

FY26 was a year of stable revenue and compressed profitability for Aarti Pharmalabs, with reported earnings shaped by higher depreciation, higher finance costs, and foreign exchange movement. The standalone numbers show a business that is still generating EBITDA above INR 400 crore, but with lower PAT because more of the operating surplus was absorbed below the EBITDA line.

The more durable message is about preparedness. The company is expanding two engines at the same time: Atali for intermediates and CDMO CMO growth, and Tarapur for Xanthine derivatives scale and mix. It has also put a medium-term target on the table, aiming for 15 to 18 percent revenue and EBITDA CAGR over 3 to 4 years, supported by capex at about FY26 levels in FY27.

The theme that emerges is disciplined execution under a heavier investment cycle. If the new capacities ramp as scheduled and customer demand tracks management expectations, FY26 may be remembered less for its profit decline and more as the setup year for the next leg of growth.